Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Novel vaccine offers hope in fight against avian flu
The vaccine reduces the level of avian flu virus chickens shed into the environment.
“Our improved vaccine could help prevent the spread of flu amongst vaccinated birds" - Prof. Munir Iqbal.

A novel vaccine for avian influenza that produces a faster and stronger immune response in chickens compared to current vaccines has been developed by The Pirbright Institute.

The vaccine, reported in the journal npj Vaccines, protects chickens against signs of the H9N2 avian flu strain and reduces the level of virus they shed into the environment. Researchers note an antibody response in chickens as early as six days after they had received the vaccination.

Avian flu vaccines are traditionally produced in chicken eggs. But in this study, researchers made the vaccine in laboratory cultures of insect cells – a technique that makes it easier and less expensive to produce. 

The vaccine works by tagging flu virus proteins with a marker that makes it easier for immune cells, known as Antigen Presenting Cells (APCs), to efficiently capture and process the tagged proteins for triggering an immune response. 

The team specifically tagged the influenza virus haemagglutinin protein (HA) and directed it to target CD83, a protein on the chicken APCs, demonstrating for the first time that this can be used as an effective vaccine. 

“By targeting HA to chicken immune cells, we have generated a powerful addition to the armoury of poultry vaccines,” explained Professor Munir Iqbal, head of Pirbright’s avian influenza virus group. “Our improved vaccine could help prevent the spread of flu amongst vaccinated birds, which is essential for protecting poultry welfare, increasing food production, and reducing the risk of avian influenza spreading to humans.”

As the vaccine does not contain any live flu virus, it is also safer. Researchers say that no specialist high containment facilities are needed for its manufacture – a quality that makes it very attractive for large-scale manufacture.

Work is now underway to assess the vaccine’s potential for commercial production and use in the field.  

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.